Nektar Therapeutics Investor Presentation — January 2021

Document content

J.P . Morgan Healthcare Conference

January 11, 20212This presentation includes forward -looking statements regarding Nektar’s proprietary drug

candidates, the timing of the start of and plans for ongoing or planned clinical trials with

partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory

decisions, and future availability of clinical trial data. Actual results could differ materially, and

these statements are subject to important risks detailed in Nektar's filings with the SEC including

the Form 10 -Q filed on November 6, 2020. Nektar undertakes no obligation to update forward-

looking statements as a result of new information or otherwise.Nektar is Developing Innovative Medicines for Patients with Cancer

and Autoimmune Diseases

NKTR -358Systemic Lupus Erythematosus LY3471851 / NKTR -358

Ulcerative Colitis LY3471851 / NKTR -358

Psoriasis LY3471851 / NKTR -358

Atopic Dermatitis LY3471851 / NKTR -358

BEMPEG COVID -19 BEMPEG

NKTR -255 Virology NKTR -255Bempegaldesleukin

(NKTR -214)Metastatic Melanoma BEMPEG + OPDIVO® vs. OPDIVO®

Renal Cell Carcinoma BEMPEG + OPDIVO® vs. TKI

Muscle -invasive Bladder Cancer BEMPEG + OPDIVO® vs. OPDIVO®

Adjuvant Melanoma BEMPEG + OPDIVO® vs. OPDIVO®

Bladder Cancer BEMPEG + OPDIVO®

Renal Cell Carcinoma BEMPEG + OPDIVO® + TKI

1L NSCLC BEMPEG + KEYTRUDA®

Head & Neck SCC BEMPEG + VB10.NEO

NKTR -262 Multiple Solid Tumors NKTR -262 + BEMPEG

NKTR -255R/R NHL or Multiple Myeloma NKTR -255 + RITUXAN®or DARZALEX FASPRO®

Head & Neck and Colorectal NKTR -255 + ERBITUX®

Program Indication Study Preclinical Phase 1 Phase 2 Phase 3

Registrational Study

Registrational Study

Registrational Study

Preview truncated — download the full document for the complete content.